Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/cells9071619 http://scihub22266oqcxt.onion/10.3390/cells9071619 32635598!7408018!32635598     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cells 2020 ; 9 (7): ä Nephropedia Template TP {{tp|p=32635598|t=2020. Canonical and Noncanonical Autophagy as Potential Targets for COVID-19 |pdf=|usr=}}{{32635598}} gab.com Text Canonical and Noncanonical Autophagy as Potential Targets for COVID-19 JO: Cells http://www.kidney.de/pget.php?&tw=1&pmid=32635598 #FOAvip The SARS-CoV-2 pandemic necessitates a review of the molecular mechanisms underlying cellular infection by coronaviruses, in order to identify potential therapeutic targets against the associated new disease (COVID-19). Previous studies on its counterparts prove a complex and concomitant interaction between coronaviruses and autophagy. The precise manipulation of this pathway allows these viruses to exploit the autophagy molecular machinery while avoiding its protective apoptotic drift and cellular innate immune responses. In turn, the maneuverability margins of such hijacking appear to be so narrow that the modulation of the autophagy, regardless of whether using inducers or inhibitors (many of which are FDA-approved for the treatment of other diseases), is usually detrimental to viral replication, including SARS-CoV-2. Recent discoveries indicate that these interactions stretch into the still poorly explored noncanonical autophagy pathway, which might play a substantial role in coronavirus replication. Still, some potential therapeutic targets within this pathway, such as RAB9 and its interacting proteins, look promising considering current knowledge. Thus, the combinatory treatment of COVID-19 with drugs affecting both canonical and noncanonical autophagy pathways may be a turning point in the fight against this and other viral infections, which may also imply beneficial prospects of long-term protection. Twit Text FOAVip Canonical and Noncanonical Autophagy as Potential Targets for COVID-19 ????Cells http://www.kidney.de/pget.php?&tw=1&pmid=32635598 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32635598 #FOAvip English Wikipedia <ref>{{Cite pmid|32635598}}</ref> Canonical and Noncanonical Autophagy as Potential Targets for COVID-19 #MMPMID32635598 Bello-Perez M; Sola I; Novoa B; Klionsky DJ; Falco A Cells 2020[Jul]; 9 (7): ä PMID32635598show ga The SARS-CoV-2 pandemic necessitates a review of the molecular mechanisms underlying cellular infection by coronaviruses, in order to identify potential therapeutic targets against the associated new disease (COVID-19). Previous studies on its counterparts prove a complex and concomitant interaction between coronaviruses and autophagy. The precise manipulation of this pathway allows these viruses to exploit the autophagy molecular machinery while avoiding its protective apoptotic drift and cellular innate immune responses. In turn, the maneuverability margins of such hijacking appear to be so narrow that the modulation of the autophagy, regardless of whether using inducers or inhibitors (many of which are FDA-approved for the treatment of other diseases), is usually detrimental to viral replication, including SARS-CoV-2. Recent discoveries indicate that these interactions stretch into the still poorly explored noncanonical autophagy pathway, which might play a substantial role in coronavirus replication. Still, some potential therapeutic targets within this pathway, such as RAB9 and its interacting proteins, look promising considering current knowledge. Thus, the combinatory treatment of COVID-19 with drugs affecting both canonical and noncanonical autophagy pathways may be a turning point in the fight against this and other viral infections, which may also imply beneficial prospects of long-term protection. |*Autophagy/drug effects[MESH] |Antiviral Agents/pharmacology/therapeutic use[MESH] |Apoptosis[MESH] |Autophagy-Related Proteins/antagonists & inhibitors/metabolism[MESH] |Betacoronavirus/classification/physiology[MESH] |COVID-19[MESH] |Capsid Proteins/metabolism[MESH] |Coronavirus Infections/drug therapy/*pathology/virology[MESH] |Coronavirus Nucleocapsid Proteins[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/drug therapy/*pathology/virology[MESH] |SARS-CoV-2[MESH]Canonical and Noncanonical Autophagy as Potential Targets for COVID-19(epmc).pdf DeepDyve Pubget Overpricing